ArticleCancer discovery2018
Genetic Mechanisms of Immune Evasion in Colorectal Cancer.
Registry-linked trialAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05504252 (METIMMOX-2), which is not on this map. Cited by 338 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
338citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05504252 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Who cites it
338 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A meta-analysis identifies driver genes and characterizes the molecular epidemiology of colorectal cancer.Scientific reports · 2026Pooled it
- Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.British journal of cancer · 2026Trial
- Trial
- Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan.Cell reports. Medicine · 2025Trial
- First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.British journal of cancer · 2024Trial
- Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.Nature medicine · 2024Trial
- Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer.British journal of cancer · 2022Trial
- Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression.Oncoimmunology · 2026Article
- Article
- The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy.Cancer medicine · 2026Article
- Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab.ESMO gastrointestinal oncology · 2026Article
- Review
- Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies.Molecular cancer · 2026Review
- Review
- Genomic landscape and clinical characteristics of ERBB2/HER2-mutated colorectal cancers.The oncologist · 2026Article
- Development and validation of a stromal myeloid-fibrotic index and a tumor-intrinsic immune evasion index for molecular stratification in colorectal cancer.Functional & integrative genomics · 2026Article
- Metastasis-associated DNA methylation alterations persist after accounting for immune and stromal cell heterogeneity in primary colorectal tumors.Research square · 2026Article
- Chronic stress and cancer progression through neuro‑endocrine‑immune networks (Review).Oncology reports · 2026Review
- Multi-layer molecular profiling defines an immune-active colorectal cancer subtype with therapeutic relevance.Molecular therapy. Nucleic acids · 2026Article
278 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors.
Catherine S Grasso *Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California. cgrasso@mednet.ucla.edu.
Marios Giannakis *Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Daniel K Wells *Parker Institute for Cancer Immunotherapy, San Francisco, California.
Tsuyoshi HamadaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Xinmeng Jasmine MuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Michael QuistDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Jonathan A NowakProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Reiko NishiharaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zhi Rong QianDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kentaro InamuraDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6444-3861
Teppei MorikawaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Katsuhiko NoshoDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Gabriel Abril-RodriguezDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Charles ConnollyPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Helena Escuin-OrdinasDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Milan S GeybelsPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
William M GradyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-0129-7809
Li HsuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Siwen Hu-LieskovanDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Jeroen R HuyghePublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Yeon Joo KimDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Paige KrystofinskiDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Mark D M LeisersonDepartment of Computer Science and Center for Computational Molecular Biology, Brown University, Providence, Rhode Island.
Dennis J MontoyaDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
Brian B NadelDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
Matteo PellegriniDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
Colin C PritchardDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.
Cristina Puig-SausDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Elleanor H QuistDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Ben J RaphaelDepartment of Computer Science and Center for Computational Molecular Biology, Brown University, Providence, Rhode Island.
Stephen J SalipanteDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.
Daniel Sanghoon ShinDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Eve ShinbrotHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
Brian ShirtsDepartment of Laboratory Medicine, University of Washington, Seattle, Washington.
Sachet ShuklaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Janet L StanfordPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Wei SunPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jennifer TsoiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California.
Alexander Upfill-BrownDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
David A WheelerHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Ming YuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Syed H ZaidiOntario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada.
Jesse M ZaretskyDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Stacey B GabrielBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Eric S LanderBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Levi A GarrawayDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Thomas J HudsonOntario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada.
Charles S FuchsChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Antoni RibasDepartment of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
Shuji OginoBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Funding
Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6MUCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8MValidity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MUCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MMolecular pathological epidemiology of colorectal cancerU01CA137088 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2009 to 2018
$21.8MTransdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6MCancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0MCancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5MNCATS NIH HHS KL2 TR001100NCATS NIH HHS UL1 TR001881NCI NIH HHS K07 CA190673NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA168585NCI NIH HHS P50 CA127003NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA169141NCI NIH HHS R01 CA194663NCI NIH HHS R35 CA197633NCI NIH HHS R35 CA197735NCI NIH HHS R50 CA211482NCI NIH HHS T32 CA009120NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA206110NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA186107NHGRI NIH HHS R01 HG007069NHGRI NIH HHS U54 HG003067NIAMS NIH HHS P50 AR063020NIH HHS S10 OD020069NLM NIH HHS T32 LM012424
Abstract
To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability-high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of
Indexed as
Tumor Escapebeta 2-MicroglobulinColorectal NeoplasmsDNA Copy Number VariationsDNA MethylationGerm-Line MutationHLA AntigensHumansLoss of HeterozygosityMicrosatellite InstabilityWnt Signaling PathwayB2M protein, humanbeta 2-MicroglobulinHLA Antigens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05504252ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.